Relevance of plasma distribution of microRNA-148a in Chinese population and hyperlipidemia

Abstract

Abstract:

AIM:To detect the distribution of miR-148a level in Chinese people's plasma, and to explore the different expression level of miR-148a in plasma between healthy subjects and hyperlipidemia patients. METHODS: According to the clinical trial scheme, plasma samples of 52 patients with hyperlipidemia and 77 cases of healthy subjects were collected. RT-qPCR was used to determine the expression of miR-148a level. Shapiro-Wilk test as a way of normality test to the experimental data. Two independent sample t-test or one-way ANOVA was used to analyze the difference between groups. RESULTS:129 cases of subjects were quartile grouped by miR-148a level, and the △Ct of miR-148a were 1.65±0.80，3.91±0.64，5.68±0.61 and 8.21±1.16, respectively. The difference between groups was statistically significant (P<0.05). Whereas, the △Ct of miR-148a of the healthy subjects group and patients with hyperlipidemia group were 4.81±2.75 and 4.84±2.26, respectively. There was no statistically significant difference between the two groups (P>0.05).CONCLUSION: The expression of miR-148a in Chinese people's plasma is normally distributed, and the difference between four groups is statistically significant. There is no difference between healthy subjects group and patients with hyperlipidemia group, suggesting that miR-148a may not relate to hyperlipidemia.

Key words: miR-148a, expression level, distribution, Real-time quantitative polymerase chain reaction, hyperlipidemia

CLC Number:

R968

LI Xi, JIN Gaofeng, LIU Zhijun, LI Xinhua, LIU Mingyi, ZHANG Hong, XIONG Yuqing. Relevance of plasma distribution of microRNA-148a in Chinese population and hyperlipidemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 659-663.

References

［1］Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma［J］.Br J Haematol，2008, 141(5): 672-675.
［2］Kloosterman WP, Plasterk RH.The diverse functions of micrornas in animal development and disease［J］. Dev Cell, 2006, 11(4):441-450.
［3］Stefani G, Slack FJ. Small non-coding RNAs in animal development［J］. Nat Rev Mol Cell Biol, 2008, 9(3):219-230.
［4］Wagschal A, Najafi-Shoushtari SH, Wang L, et al.Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis［J］. Nat Med, 2015, 21(11)：1290-1297.
［5］高军平, 向邦德, 倪航航, 等. microRNA-224在肝细胞癌组织和血浆中表达的相关性［J］.中国现代医学杂志, 2011, 21(32): 4012-4016.
［6］Ruoquan Y, Wanpin N, Qiangsheng X, et al.Correlation between plasma miR-122 expression and liver injury induced by hepatectomy［J］.J Int Med Res，2014,42(1):77-84.
［7］Takeuchi-Yorimoto A, Yamaura Y, Kanki M, et al. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease［J］. Toxicol Lett,2016, 258: 159-167.
［8］Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted players［J］. Mol Cancer, 2013, 12(1): 43.
［9］Goedeke L, Rotllan N, Canfrán-Duque A, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels［J］. Nat Med,2015, 21(11):1280-1289.
［10］Rotllan N, Price N, Pati P, et al.MicroRNAs in lipoprotein metabolism and cardiometabolic disorders［J］. Atherosclerosis, 2016, 246(10): 352-360.
［11］Mitchell PS, Parkin RK, Kroh EM, et al.Circulating microRNAs as stable blood-based markers for cancer detection［J］. Proc Natl Acad Sci USA,2008, 105(30):10513-10518.
［12］Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform［J］.Gynecol Oncol, 2009, 112(1):55-59.
［13］吴瑞珊, 温旺荣.外周血miRNA的诊断意义［J］.分子诊断与治疗杂志, 2012, 4(2): 131-136.
［14］Kroh EM, Parkin RK, Mitchell PS, et al.Analysis of circulating microRNAbiomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)［J］.Methods, 2010, 50(4):298-301.

[1]	ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei. Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
[2]	WU Zhiyong, LIU Bingrong, LI Bin, TANG Rui. Value of red blood cell distribution width in predicting early poor neurologic improvement after intravenous thrombolysis in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 307-314.
[3]	GUO Lu, ZHONG Zhendong, HAN Yicen, SHI Yi, YANG Yong, BIAN Yuan, LIU Xiaoshu, ZHANG Jing, LANG Qin, ZHONG Tian. Effects of different administration methods on the pharmacokinetics and tissue distribution of ribavirin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 25-32.
[4]	XU Ke, GAO Junwei, LIU Peng, SHEN Zhengri, JIA Hui, WU Chenguang, TIAN Feng, WANG Lifan, LI Ping. Tangshen formula improves cholesterol uptake and efflux of macrophages induced by high lipid via activating PGC-1α/LXR/ABCA1 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 978-985.
[5]	WANG Xiangyi, SHENG Jie, WANG Xiu, GUO Yan, CHEN Zhiwu. Distribution of deuterosuccinylcholine chloride in rats determined by UPLC-MS/MS method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 271-277.
[6]	LI Jiadan，LU Chen. Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 278-284.
[7]	CHEN Aiying, CHENG Min, MIAO Yunping, YE Xiaodi, TIAN Xuejun, ZHENG Gaoli. Pharmacokinetics and tissue distribution characteristics of sunitinib#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1105-1110.
[8]	XING Han, NING Chen, KONG Dexuan, CAI Hui, ZHOU Shiyu, REN Chang, KONG Ying, CHENG Yujie, CHEN Xijing. Tissue distribution and excretion study of GL-V9 in rats, a wogonin derivative with significant antitumor activity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 889-895.
[9]	ZHENG Li, MO Juanfen, WU Jiayuan, GUO Li, BAO Yi. Study on the anti-hyperlipidemia mechanisms and signaling pathways of traditional Chinese medicine Polygonum cuspidatum based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1107-1119.
[10]	YUAN Yawen, LI Yan, YANG Jin. Development and validation of a sensitive LC-MS/MS method for the determination of para-aminosalicylic acid in different tissues in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 272-280.
[11]	YAO Tianyi, YIN Shaoping, LIU Wen, ZHAO Yanlei, WANG Guangji, LI Juan. Biodistribution and biological evaluation of paclitaxel polymer micelles [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1207-1214.
[12]	YANG Yi, GUAN Qiaobing, GUO Li, LI Wenyan, ZHANG Hui, HAN Chenyang. Alternate dosing of ezetimibe and colestipol on regulating lipid metabolism in hyperlipidemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1112-1116.
[13]	JIANG Hai, JIANG Guozhi, CHEN Zhong, LI Zhenjiang. Lipid-lowering effects of combined use of curcuma longa L.extracts and atorvastatin calcium in hyperlipidemia mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 48-51.
[14]	WANG Pan, XIE Shan-shan, GUO Jian-jun, BU Hai-zhi, CHEN Xi-jing. Research overview in absorption, distribution, metabolism and excretion of dihydropyridine calcium antagonists [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 937-943.
[15]	BAI Yun-xia. Study of the effects and the mechanism of resveratrol on platelet aggregation in hyperlipidemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 769-773.